Newsroom > Articles


Medexprim, the European leader in multimodal Real-World datasets for clinical research, is pleased to announce its partnership with Avicenna.AI.

As a Real-World Data specialist, Medexprim deploys its software suite and services in an expanding network of leading European university hospitals. In compliance with GDPR, Medexprim solutions extract, aggregate, curate, enrich, and de-identify health data from multiple sources to deliver complex, regulatory-grade, multimodal, and multicentric datasets to serve oncology, neurology, cardiology and rare diseases.

Founded in 2018, Avicenna.AI aims to develop AI-based radiology solutions that allow healthcare professionals to accelerate the therapeutic decision-making process and improve patient outcomes. Among different products, Avicenna.AI provides AI solutions that can support radiology departments in detecting and treating highly morbid thoraco-abdominal conditions, from pulmonary embolism to aortic dissection.

Through this partnership, Medexprim will provide Avicenna.AI with tailored lung datasets to help them accelerate the validation of their pulmonary embolism AI radiology solutions.

Regarding the partnership, Nicolas Dubost, Head of Partnerships at Medexprim, says: We are thrilled to provide the right data needed for validation towards critical development steps such as FDA approval and CE marking, and to accompany an innovative company like Avicenna.AI in this process “.

“We are excited to collaborate with a french company such as Medexprim, which shares our same core values and commitment to excellence. Thanks to this partnership, we will be able to access high-quality and real-world datasets to expand our portfolio”, said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI.

French version of the PR
Press contacts:
Avicenna.AI – Stéphanie Bellavia –
Medexprim – Anne-Sophie Labeta –

About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning.

About Medexprim
Real-World Evidence for Better Care
Medexprim is the European leader in secure imaging and clinical data extraction to accelerate medical research. As a Real-World Data specialist, Medexprim builds bridges between European academic hospitals and pharmaceutical, AI, and medical device companies. In compliance with the GDPR, Medexprim helps hospitals boost their clinical research strategy and valorize their data through a software suite and services designed with and for clinicians. Medexprim provides its partners with secure access to complex, regulatory-grade, multimodal, and multicentric datasets to serve oncology, cardiology, neurology, and rare diseases and help solve the “one patient, one disease, one treatment” equation to accelerate personalized medicine.
Website – LinkedIn

BC Platforms acquires Medexprim, paving the way for Global Leadership…

BC Platforms, a global leader in healthcare data management and analytics, today announced it…

RSNA 2023: Medexprim brings European multi-imaging datasets to Innovation.

Medexprim, a leading European innovator in the field of Real-World Data and healthcare solutions,…

Medexprim appoints Doctor Mercedes Serra as Head of Data Science…

Medexprim is proud to announce the appointment of Mercedes Serra as the Head of…

IQVIA clôture l’édition 2023 de son Accelerator Program, en collaboration…

IQVIA, spécialiste mondial d’analyses avancées, de solutions technologiques et de services de recherche clinique…